Ain457a (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
271 | Ankylosing spondylitis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01109940 (ClinicalTrials.gov) | April 2010 | 22/4/2010 | Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis | An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Moderate to Severe Ankylosing Spondylitis | Ankylosing Spondylitis | Biological: AIN457A | Novartis Pharmaceuticals | NULL | Completed | 18 Years | 65 Years | Both | 39 | Phase 2 | United States;Germany;Netherlands;United Kingdom |